Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income (2023 - 2025)

Historic Net Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Net Income fell 15494.42% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 2158.68%. This contributed to the annual value of -$204.7 million for FY2024, which is 838.43% down from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Net Income stood at -$19.7 million for Q3 2025, which was down 15494.42% from -$30.3 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Net Income ranged from a high of $35.8 million in Q3 2024 and a low of -$112.4 million during Q2 2024
  • Over the past 3 years, Day One Biopharmaceuticals' median Net Income value was -$46.0 million (recorded in 2023), while the average stood at -$43.7 million.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 17766.49% in 2024, then crashed by 15494.42% in 2025.
  • Quarter analysis of 3 years shows Day One Biopharmaceuticals' Net Income stood at -$54.5 million in 2023, then dropped by 20.61% to -$65.7 million in 2024, then surged by 70.04% to -$19.7 million in 2025.
  • Its last three reported values are -$19.7 million in Q3 2025, -$30.3 million for Q2 2025, and -$36.0 million during Q1 2025.